Summary & Overview
CPT 64605: Trigeminal Nerve Neurodestructive Injection
CPT code 64605 denotes a neurodestructive injection performed at or near the trigeminal nerve to ablate nerve tissue and disrupt sensory or motor function in the face or scalp. This procedure is clinically significant as a treatment option for severe facial pain syndromes such as trigeminal neuralgia and may be used to manage refractory neuropathic pain or to intentionally impair facial motor function for therapeutic reasons. Nationally, the code is relevant to payers and providers involved in pain management, neurosurgery, and outpatient procedural care.
Key payers examined include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical indications and typical sites of service, how the code maps to procedural workflows, and what to expect in payer coverage considerations. The publication also summarizes benchmarks and common billing practices where available, highlights relevant policy updates affecting utilization and prior authorization, and situates CPT code 64605 within the broader clinical context of trigeminal nerve interventions.
This briefing is intended for national audiences of clinicians, coding professionals, and policy analysts seeking a practical summary of procedural intent, payer relevance, and topics to explore further when preparing claims or reviewing coverage policies.
Billing Code Overview
CPT code 64605 describes a procedure in which a provider intentionally destroys part of a nerve by injecting a neurodestructive agent at or near the trigeminal nerve. The service is performed to disrupt nerve conduction for purposes such as obstructing motor function of the face or scalp and to relieve severe facial pain from conditions like trigeminal neuralgia (tic douloureux).
Service type: Neurodestructive injection targeting trigeminal nerve
Typical site of service: Outpatient procedural setting or ambulatory surgery center, often performed by pain medicine, neurosurgery, or interventional neurology specialists.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 68-year-old patient with a multi-year history of right-sided trigeminal neuralgia presents with recurrent, severe lancinating facial pain refractory to optimized medical therapy (carbamazepine and gabapentin) and prior partial response to microvascular decompression. After multidisciplinary evaluation by neurology and pain management, the patient is scheduled for a percutaneous trigeminal nerve neurolytic injection to relieve intractable facial pain. The procedure is performed in an outpatient ambulatory surgery center under monitored anesthesia care. The interventional pain physician obtains informed consent, reviews imaging (MRI brain with trigeminal nerve protocol), confirms target division of the trigeminal nerve, assembles neurodestructive agent (e.g., absolute alcohol or glycerol), and positions the patient supine. Under fluoroscopic guidance with sterile technique, a percutaneous needle is advanced to the foramen ovale/Meckel’s cave region. Contrast is injected to confirm location, then the neurolytic agent is injected while monitoring neurologic status and hemodynamics. Post-procedure, the patient is observed in recovery for vital signs, facial motor and sensory function, and discharged with post-procedure instructions and a scheduled follow-up to assess pain relief and potential complications (facial numbness, corneal reflex changes, dysesthesia). Documentation includes the targeted trigeminal branch, laterality, type and volume of neurolytic agent, imaging guidance used, anesthesia modality, informed consent, and any immediate complications.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 |